Loading...

Teleflex Incorporated

TFXNYSE
Healthcare
Medical - Instruments & Supplies
$129.42
$4.81(3.86%)

Teleflex Incorporated (TFX) Financial Performance & Income Statement Overview

Review Teleflex Incorporated (TFX) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
2.45%
2.45%
Operating Income Growth
-70.17%
70.17%
Net Income Growth
-80.45%
80.45%
Operating Cash Flow Growth
24.50%
24.50%
Operating Margin
10.52%
10.52%
Gross Margin
55.59%
55.59%
Net Profit Margin
6.31%
6.31%
ROE
4.49%
4.49%
ROIC
4.80%
4.80%

Teleflex Incorporated (TFX) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Teleflex Incorporated TFX financial performance.

MetricQ2 2025Q1 2025Q4 2024Q3 2024
Revenue$780.89M$700.67M$795.41M$764.38M
Cost of Revenue$349.80M$311.23M$355.49M$334.20M
Gross Profit$431.08M$389.44M$439.92M$430.17M
Gross Profit Ratio$0.55$0.56$0.55$0.56
R&D Expenses$38.52M$36.40M$44.55M$38.73M
SG&A Expenses$215.08M$222.71M$254.55M$247.26M
Operating Expenses$253.60M$263.87M$559.50M$285.98M
Total Costs & Expenses$603.41M$575.10M$905.79M$620.19M
Interest Income-$1.64M$1.92M$2.26M$2.30M
Interest Expense$21.71M$18.54M$18.64M$21.06M
Depreciation & Amortization$0.00-$32.38M$71.79M$68.64M
EBITDA$122.58M$95.10M-$36.33M$220.25M
EBITDA Ratio$0.16$0.14-$0.05$0.29
Operating Income$122.58M$125.57M-$110.38M$149.31M
Operating Income Ratio$0.16$0.18-$0.14$0.20
Other Income/Expenses (Net)$12.66M-$16.63M-$16.38M-$18.76M
Income Before Tax$135.25M$108.94M-$126.76M$130.55M
Income Before Tax Ratio$0.17$0.16-$0.16$0.17
Income Tax Expense$12.66M$13.84M$9.90M$19.63M
Net Income$122.58M$95.002M-$136.66M$111.004M
Net Income Ratio$0.16$0.14-$0.17$0.15
EPS$2.77$2.08-$2.95$2.38
Diluted EPS$2.77$2.07-$2.95$2.36
Weighted Avg Shares Outstanding$44.27M$45.78M$46.32M$46.72M
Weighted Avg Shares Outstanding (Diluted)$44.33M$45.93M$46.37M$47.01M

The company's financials show resilient growth, with revenue advancing from $764.38M in Q3 2024 to $780.89M in Q2 2025. Gross profit remained healthy with margins at 55% in Q2 2025 compared to 56% in Q3 2024. Operating income hit $122.58M last quarter, sustaining a consistent 16% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $122.58M. Net income rose to $122.58M, while earnings per share reached $2.77. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;